Compounded Semaglutide in 2026: FDA Status, Shortage Update, and Your Options

A Quick History: How Compounded Semaglutide Became Common

When Ozempic (semaglutide) demand exploded in 2022-2023, Novo Nordisk couldn't keep up. The FDA officially listed semaglutide on its drug shortage list, which triggered a legal pathway for compounding pharmacies to produce their own versions of the medication.

Compounded semaglutide is chemically identical to brand-name Ozempic or Wegovy but is produced by FDA-registered pharmacies rather than Novo Nordisk. The result: patients who couldn't access or afford brand-name semaglutide (often $900-$1,300/month) could get compounded versions for $150-$400/month.

Millions of patients accessed GLP-1 treatment through this pathway. It fundamentally changed who could afford these medications.

What Changed: The FDA Shortage Resolution

In late 2024, the FDA declared the semaglutide shortage resolved. This was significant because the drug shortage designation is what authorized 503A and 503B compounding pharmacies to produce copies of brand-name drugs.

When a shortage is resolved: - 503A compounding pharmacies (patient-specific, traditional compounding) lose authorization to compound copies of the drug for non-patient-specific reasons - 503B outsourcing facilities (larger-scale, FDA-registered, non-patient-specific production) also lose authorization to produce generic copies

The FDA set enforcement deadlines, after which producing compounded semaglutide without the shortage exception would violate the Federal Food, Drug, and Cosmetic Act.

The Nuances: It's Not a Simple Ban

The situation is more complex than "compounded semaglutide is now illegal."

503A pharmacies can still compound with a valid prescription: A licensed physician can still prescribe compounded semaglutide for a patient with a documented clinical need — particularly when there's a medical reason the patient can't use brand-name product (documented allergy to excipients, need for a different concentration or formulation, economic barrier). The question is whether insurers and regulators will scrutinize these prescriptions more closely.

Legal challenges have complicated the timeline: Multiple compounding industry groups filed legal challenges to the FDA's shortage resolution determination, arguing the supply remains inadequate for actual patient demand. Courts have granted temporary injunctive relief in some cases, pausing enforcement.

The FDA has been deliberate about enforcement: Rather than an immediate hard cutoff, the FDA has signaled enforcement discretion and phased timelines, particularly for patients already on compounded semaglutide.

Understanding 503A vs 503B Pharmacies

503A pharmacies are traditional compounding pharmacies that fill patient-specific prescriptions. Think of your local compounding pharmacy. They can legally compound medications not commercially available or when there's a documented patient-specific medical need. During the shortage, they could compound semaglutide broadly. Post-shortage, this pathway narrows significantly.

503B outsourcing facilities are larger-scale operations that produce compounded medications without patient-specific prescriptions — essentially producing inventory in advance. They face more stringent FDA oversight (similar to pharmaceutical manufacturing) but also had broader authorization during the shortage. Post-shortage resolution, their authorization to produce semaglutide copies is the most directly challenged.

What Patients Should Know

If you're currently on compounded semaglutide: In most cases, you can continue for now. The FDA's enforcement approach has been graduated. However, the regulatory environment may tighten through 2026.

If cost is your primary concern: The situation is evolving. Novo Nordisk has expanded affordability programs (Ozempic's $99/month patient program). Compounded tirzepatide remains available and may be a viable alternative for patients where cost is the barrier.

If you're starting fresh: Access to compounded semaglutide is becoming less consistent. Telehealth platforms that built their business around compounded GLP-1s are adapting — some are shifting to brand-name with manufacturer coupons, others are pivoting to tirzepatide.

Tirzepatide: The Practical Alternative

As of 2026, tirzepatide is still on the FDA shortage list (as of this writing). This means compounded tirzepatide remains legally authorized through 503A and 503B pharmacies.

Moreover, tirzepatide has superior efficacy data compared to semaglutide — 20-22% average weight loss vs 15%. For many patients, the switch from compounded semaglutide to compounded tirzepatide is a straightforward clinical decision.

How Marrow Navigates This

Marrow works with FDA-registered compounding pharmacies and monitors the regulatory landscape closely. We prescribe based on each patient's clinical picture and what's currently legally and clinically appropriate.

If you're concerned about access to compounded GLP-1 medications, the best first step is a consultation to understand your specific options — brand-name with manufacturer assistance programs, compounded alternatives where legally available, or evidence-based alternatives like tirzepatide.

The GLP-1 landscape is still evolving rapidly. What's clear is that patient access to these medications — whatever form it takes — is a public health priority, and the regulatory and commercial infrastructure is adapting to meet it.